Approximately 32-44% of the adult US population has hypertension, with one of the many complications
being hypertensive retinopathy. In one study, the prevalence of retinopathy was found to be 85% amongst
those with severe hypertension, and 25% for those with mild hypertension. Retinal consequences of
hypertension include arteriolar narrowing, hemorrhages, cotton wool spots (localized hypoxia), and optic
disk swelling. Other retinal changes include hyalinization of arteriolar walls, thickening of the vascular
basement membrane, closure of capillaries, smooth muscle degeneration, and blood-retinal barrier
dysfunction. Additionally, hypertension is a major risk factor for the highly threatening events of retinal artery
or vein occlusion. The primary treatment for hypertensive retinopathy is to reduce blood pressure; however,
consequences of the disease including narrowing of arterioles persist even following anti-hypertension
medication. Therefore, a better knowledge of the mechanisms of the disease could lead to the development
of additional and more effective therapeutic options. Our overall hypothesis is that the vascular
complications of hypertensive retinopathy are due phenotypic changes in endothelial and smooth muscle
cells, with vessel wall remodeling limiting recovery even with anti-hypertensive medication. The specific
aims are to: (1) determine the sex-dependent expression of the glycocalyx in the retina, and determine the
consequences of hypertension on this expression, (2) examine the sex-dependent expression of platelet
endothelial adhesion molecule-1 and vascular endothelial cadherin in the retina, and test the hypothesis
that changes in these junctional molecules in the hypertensive retina are due to endothelial-to-
mesenchymal transition, and (3) test the hypothesis that remodeling of blood vessel walls in the SHR retina
induces susceptibility to poor retinal perfusion when high blood pressure is reduced to normal.